Scholarlink

Background <p>Glaucoma is a leading cause of irreversible blindness, characterized by the progressive degeneration of retinal ganglion cells (RGCs). Activation of the Tropomyosin receptor kinase B (TrkB) pathway by mature brain-derived neurotrophic factor (mBDNF) has emerged as a promising neuroprotective strategy, given its critical role in promoting RGC survival in preclinical models.</p> Methods <p>We advanced the development of a bicistronic adeno-associated viral (AAV) gene therapy vector engineered to co-express human TrkB and mBDNF. The vector was optimized with fully human transgene sequences and evaluated for functional expression and dose scalability to support clinical translation. Expression tracking and efficiency were enhanced by incorporating a self-cleaving 2A peptide sequence.</p> Results <p>In a mouse model of optic nerve crush, intravitreal administration of 1.52E8 to 7.60E8 genome copies (GC)/eye significantly mitigated RGC damage. In a rat model of laser-induced ocular hypertension, doses ranging from 3.80E8 to 1.90E9 GC/eye preserved both visual function and RGC survival. The 2A peptide facilitated efficient co-expression of TrkB and mBDNF while minimizing interference from endogenous protein pathways.</p> Conclusions <p>These findings demonstrate that co-expression of human TrkB and mBDNF via a bicistronic AAV vector yields robust, dose-dependent neuroprotection and sustained transgene expression in two distinct models of glaucomatous injury. This gene therapy represents a promising first-in-class candidate for the treatment of glaucoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dose-ranging and further therapeutic evaluation of a bicistronic humanized TrkB-BDNF gene therapy for glaucoma in rodents

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月18日

查看全文
  • Andrew Osborne,
  • Tasneem Z. Khatib,
  • Michael Whitehead,
  • Terrance Mensah,
  • Sadat Yazdouni,
  • Bart Nieuwenhuis,
  • Zara Ali,
  • Jared Ching,
  • Robert Watt,
  • Naoki Kishi,
  • Naoki Kozono,
  • James R. Tribble,
  • Peter S. Widdowson,
  • Keith R. Martin

摘要

Background

Glaucoma is a leading cause of irreversible blindness, characterized by the progressive degeneration of retinal ganglion cells (RGCs). Activation of the Tropomyosin receptor kinase B (TrkB) pathway by mature brain-derived neurotrophic factor (mBDNF) has emerged as a promising neuroprotective strategy, given its critical role in promoting RGC survival in preclinical models.

Methods

We advanced the development of a bicistronic adeno-associated viral (AAV) gene therapy vector engineered to co-express human TrkB and mBDNF. The vector was optimized with fully human transgene sequences and evaluated for functional expression and dose scalability to support clinical translation. Expression tracking and efficiency were enhanced by incorporating a self-cleaving 2A peptide sequence.

Results

In a mouse model of optic nerve crush, intravitreal administration of 1.52E8 to 7.60E8 genome copies (GC)/eye significantly mitigated RGC damage. In a rat model of laser-induced ocular hypertension, doses ranging from 3.80E8 to 1.90E9 GC/eye preserved both visual function and RGC survival. The 2A peptide facilitated efficient co-expression of TrkB and mBDNF while minimizing interference from endogenous protein pathways.

Conclusions

These findings demonstrate that co-expression of human TrkB and mBDNF via a bicistronic AAV vector yields robust, dose-dependent neuroprotection and sustained transgene expression in two distinct models of glaucomatous injury. This gene therapy represents a promising first-in-class candidate for the treatment of glaucoma.